Immune Support
Overview
Peptide immunotherapy addresses both immunodeficiency (chronic infections, post-viral syndromes, cancer adjunct) and dysregulated immunity (autoimmune, allergic). Thymic peptides restore T-cell competence and innate immunity, while antimicrobial peptides like LL-37 provide direct pathogen defense. This category is particularly relevant for aging populations with immune senescence and for those recovering from chronic infections.
Recommended Peptides
- Thymosin Alpha-1 – thymic peptide that matures T-cells and promotes Treg induction via IDO pathway; FDA-designated orphan drug; used clinically in hepatitis B/C, cancer adjunct, and chronic viral infections
- Selank – anxiolytic peptide with significant immunomodulatory effects; upregulates IL-2, interferon, and NK cell activity while reducing excessive inflammatory cytokines
- LL-37 – human cathelicidin antimicrobial peptide; broad-spectrum antimicrobial and antiviral; modulates TLR signaling and promotes wound healing
- KPV – anti-inflammatory alpha-MSH fragment; reduces cytokine storm, useful in gut inflammation and systemic inflammatory conditions
- Thymulin – zinc-dependent thymic hormone; promotes T-cell differentiation and NK cell activity; declines with age
- Thymopentin – synthetic pentapeptide from thymopoietin; stimulates T-cell maturation and cytokine production; used clinically in immunodeficiency
- VIP – vasoactive intestinal peptide; potent anti-inflammatory neuropeptide; downregulates Th1/Th17 responses and promotes Treg induction
Protocols
Related Conditions
Research Summary
Thymosin Alpha-1 has the strongest immune peptide evidence: approved in 35+ countries (ZADAXIN), safety confirmed across 11,000+ subjects (PMID-38308608), and COVID-19 meta-analysis showed significant mortality reduction (PMID-37845598). LL-37 modulates TLR signaling with context-dependent pro/anti-inflammatory effects (PMID-32582207). KPV reduces intestinal inflammation via NF-kB inhibition (PMID-18061177).
Related
#condition #immune-system